Aldeyra Therapeutics (NASDAQ: ALDX) and Vical (NASDAQ:VICL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Analyst Ratings

This is a summary of current recommendations for Aldeyra Therapeutics and Vical, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aldeyra Therapeutics 0 0 6 0 3.00
Vical 0 0 3 0 3.00

Aldeyra Therapeutics presently has a consensus target price of $18.33, suggesting a potential upside of 118.25%. Vical has a consensus target price of $7.00, suggesting a potential upside of 354.55%. Given Vical’s higher possible upside, analysts plainly believe Vical is more favorable than Aldeyra Therapeutics.

Valuation & Earnings

This table compares Aldeyra Therapeutics and Vical’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aldeyra Therapeutics N/A N/A -$18.69 million ($1.40) -6.00
Vical $14.53 million 1.97 -$8.97 million ($1.07) -1.44

Vical has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Vical, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

48.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 17.7% of Vical shares are owned by institutional investors. 19.0% of Aldeyra Therapeutics shares are owned by company insiders. Comparatively, 6.0% of Vical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


This table compares Aldeyra Therapeutics and Vical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aldeyra Therapeutics N/A -67.43% -60.54%
Vical -92.13% -29.06% -23.52%

Volatility & Risk

Aldeyra Therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Comparatively, Vical has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.


Vical beats Aldeyra Therapeutics on 8 of the 12 factors compared between the two stocks.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company’s aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.

Vical Company Profile

Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, and completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with's FREE daily email newsletter.